The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb/Sanofi; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
 
Michal Kicinski
Research Funding - Pierre Fabre (Inst)
 
Anne-Sophie Govaerts
Research Funding - Pierre Fabre (Inst)
 
Isabelle Klauck
Employment - Pierre Fabre
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Monia Ouali
Employment - Pierre Fabre
 
Paul Lorigan
Honoraria - Amgen; BMS; Merck; MSD; Nektar; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - BMS (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Alexander M. Eggermont
Stock and Other Ownership Interests - IO Biotech; Sairopa; Skyline Diagnostics
Honoraria - Agenus; BIOINVENT; BioNTech; Brenus Pharma; CatalYm; Clover Health; Ellipses Pharma; EPICS; Galecto; GenOway; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Consulting or Advisory Role - Agenus; BioInvent; BIOINVENT; Brenus Pharma; CatalYm; Ellipses Pharma; EPICS; GenOway; IO BIOTECH; IO Biotech; IQVIA; ISA Pharmaceuticals; Merck; MSD; Pfizer; Pierre Fabre; Sairopa; Scorpion Therapeutics; Sellas Life Sciences; Skyline Diagnostics; TigaTx; Trained Therapeutix Discovery
Speakers' Bureau - Bristol-Myers Squibb.; Merck; MSD